Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Susumu Noguchi, Keiichiro Suminaga, Takahiro Kaki, Hiroaki Kawachi, Akari Fukao, Satoshi Terashita, Sadao Horikawa, Tatsuyoshi Ikeue, Takakazu Sugita Respiratory Medicine, Japanese Red Cross Wakayama Medical Center, Wakayama, JapanCorrespondence: Susumu NoguchiRespiratory Medicine, Japanese Red Cros...

Full description

Bibliographic Details
Main Authors:	Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-07-01
Series:	Lung Cancer : Targets and Therapy
Subjects:	lung cancer pembrolizumab adverse drug event correlation study
Online Access:	https://www.dovepress.com/correlation-of-immune-related-adverse-events-and-effects-of-pembrolizu-peer-reviewed-article-LCTT

Similar Items

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
by: Anne Schaefer, et al.
Published: (2020-04-01)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
by: Hao‐Chun Chang, et al.
Published: (2020-08-01)

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
by: Andrés F. Cardona, et al.
Published: (2021-03-01)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
by: Fanny Zulay Acero Brand, et al.
Published: (2018-03-01)

A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency
by: Kei Sonehara, et al.
Published: (2021-01-01)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)

Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
by: Sachiko Matsumoto, et al.
Published: (2020-07-01)

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
by: Xiaohong Xie, et al.
Published: (2021-01-01)

Severe gastritis due to pembrolizumab treatment in a lung cancer patient
by: Noriko Hayama, et al.
Published: (2020-10-01)

Case Report: SAPHO Syndrome Mimicking Bone Metastases During Treatment With Pembrolizumab for Non-small Cell Lung Cancer
by: Yuko Kubo, et al.
Published: (2021-07-01)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
by: Nora Möhn, et al.
Published: (2019-10-01)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
by: Elizabeth Dudnik, et al.
Published: (2021-01-01)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
by: Maria Anna Siciliano, et al.
Published: (2020-10-01)

Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report
by: Dongqi Li, et al.
Published: (2018-04-01)

Case report: reinitiating pembrolizumab treatment after small bowel perforation
by: Tim N. Beck, et al.
Published: (2019-04-01)

Pembrolizumab on pre-existing inclusion body myositis: a case report
by: Naohiro Uchio, et al.
Published: (2020-09-01)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-05-01)

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
by: Hiroshi Matsuoka, et al.
Published: (2020-07-01)

Durable complete remission after Pembrolizumab in pretreated advanced endometrial cancer: A case report
by: Bacigalupo, L., et al.
Published: (2022)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
by: Nabil E. Omar, et al.
Published: (2020-10-01)

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
by: Teppei Sugano, et al.
Published: (2019-02-01)

Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
by: Chihiro Mimura, et al.
Published: (2021-04-01)

Visceral pleural biopsy under medical thoracoscopy for the diagnosis of lung adenocarcinoma
by: Satoshi Terashita, et al.
Published: (2020-08-01)

A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer
by: Kyung Woo Kim, et al.
Published: (2021-06-01)

A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
by: Jaqueline Ghosn, et al.
Published: (2018-10-01)

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Jiang Y, et al.
Published: (2019-02-01)

Pembrolizumab-Induced Delayed-Onset Hepatitis
by: Kensuke Kanaoka, et al.
Published: (2020-11-01)

Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis
by: Mike Nguyen, et al.
Published: (2019-09-01)

Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced  Non-small Cell Lung Cancer and Its Therapeutic Effect
by: Yun WANG, et al.
Published: (2021-03-01)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
by: Vachhani P, et al.
Published: (2016-09-01)

Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?
by: Timothy Phan, et al.
Published: (2021-02-01)

Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection
by: Cheng Zhou, et al.
Published: (2019-02-01)

Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer
by: Shinya Asatani, et al.
Published: (2021-06-01)

Advanced G‐CSF‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy
by: Yohei Matsui, et al.
Published: (2020-10-01)

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
by: Saralinh Trinh, et al.
Published: (2019-01-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
by: N. Shah, et al.
Published: (2019-09-01)